GlassScriptPhysician profile
Enzo J Leone
NPI 1801894241
$14,657.48
in general payments reported to CMS, 2019-2025
43 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 92% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $5,335 · 2021: $1,543 · 2022: $1,633 · 2023: $811 · 2024: $759 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307 · Travel and Lodging: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.21 |
| Travel and Lodging | $1,599.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supreme Orthopedic Systems, LLC | $5,201.92 | 2019-2024 | |
| Arthrex, INC. | $3,619.24 | 2020 | |
| Treace Medical Concepts, INC. | $2,255.08 | 2023-2025 | |
| Smith+Nephew, INC. | $661.58 | 2019-2025 | Grafix Pl, Stravix Pl, Panta 2 |
| Horizon Therapeutics Plc | $371.57 | 2019-2023 | Krystexxa |
| Musculoskeletal Transplant Foundation INC. | $273.16 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $248.12 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $221.29 | 2019-2022 | |
| Amgen INC. | $161.87 | 2024-2025 | Krystexxa |
| Nevro Corp. | $151.24 | 2022-2024 | Senza |
| Abbvie INC. | $132.81 | 2022-2024 | |
| Organogenesis INC. | $122.39 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $116.03 | 2025 | Purified Cortrophin Gel |
| Bioventus LLC | $109.69 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Nabriva Therapeutics, Plc | $99.37 | 2020-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $82.97 | 2025 | Senza |
| Stryker Corporation | $62.50 | 2022-2024 | Iconix |
| Convatec INC. | $59.88 | 2023-2024 | |
| Sebela Pharmaceuticals INC. | $58.41 | 2021-2023 | Naftin |
| Tactile Systems Technology INC | $55.32 | 2019-2020 | |
| Orthofix Medical, INC. | $48.49 | 2023-2025 | Physio-Stim |
| Zyla Life Sciences, INC. | $48.03 | 2019 | |
| Mimedx Group, INC. | $46.01 | 2024-2025 | |
| Integra Lifesciences Corporation | $42.19 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kci USA, INC. | $41.24 | 2019-2021 | |
| Sanara Medtech INC. | $38.92 | 2023-2024 | Celleraterx |
| Merck Sharp & Dohme LLC | $34.95 | 2019 | |
| Next Science LLC | $26.93 | 2023 | Xperience, Blastx, Surgx |
| Heron Therapeutics, INC. | $24.86 | 2021 | |
| Grt US Holding, INC. | $23.78 | 2021 | |
| Averitas Pharma INC. | $22.73 | 2024 | Qutenza |
| Triad Life Sciences INC. | $21.46 | 2022 | |
| Kerecis Limited | $19.76 | 2019-2021 | |
| Fidia Pharma USA INC. | $18.46 | 2023 | Hymovis, Triluron |
| Acera Surgical, INC. | $18.42 | 2024 | Restrata Wound Matrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.90 | 2025 | Jublia |
| Reprise Biomedical, INC. | $16.11 | 2025 | Miro3d |
| Progenacare Global, LLC | $15.68 | 2024 | |
| Arthrosurface Incorporated | $15.64 | 2019 | |
| Mckesson Patient Care Solutions INC. | $14.32 | 2019 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Hartmann USA, INC. | $13.97 | 2025 | Zetuvit Plus 10x10 P10 |
| Lifenet Health | $10.19 | 2025 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enzo Leone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.